MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma

Published:2014-07-21 Issue:3 Volume:35 Page:1077-1086
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Vaira Valentina¹,Roncalli Massimo²,Carnaghi Carlo³,Faversani Alice¹⁴,Maggioni Marco¹,Augello Claudia¹⁴,Rimassa Lorenza³,Pressiani Tiziana³,Spagnuolo Gaia²,Di Tommaso Luca²,Fagiuoli Stefano⁵,Rota Caremoli Elena⁶,Barberis Massimo⁷,Labianca Roberto⁶,Santoro Armando³,Bosari Silvano¹⁴

Affiliation:

1. Division of Pathology; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy

2. Department of Medical Biotechnologies and Translational Medicine; University of Milan and Division of Pathology; IRCCS Istituto Clinico Humanitas; Rozzano Milan Italy

3. Medical Oncology and Haematology Unit; Humanitas Cancer Center; Rozzano Milan Italy

4. Department of Pathophysiology and Transplantation; University of Milan; Milan Italy

5. Division of Gastroenterology and Transplant Hepatology; Department of Medicine; Papa Giovanni XXIII Hospital; Bergamo Italy

6. Department of Oncology and Haematology; Papa Giovanni XXIII Hospital; Bergamo Italy

7. Department of Pathology; Papa Giovanni XXIII Hospital; Bergamo Italy

Funder

Fondazione Berlucchi

Fondazione Cariplo

AIRC

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12636/fullpdf

Reference40 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

3. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial;Bruix;J Hepatol,2012

4. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma;Llovet;Clin Cancer Res,2012

5. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma;Personeni;J Hepatol,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

2. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma;Frontiers in Oncology;2024-06-27

3. Low expression of miR125a-5p predicts sensitivity to sorafenib by upregulating STAT3 and HTATIP2 in hepatocellular carcinoma;2023-12-19

4. Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma;Translational Gastroenterology and Hepatology;2023-10

5. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice;Cancers;2023-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3